Idenix Pharmaceuticals News
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.
Idenix Pharmaceuticals Inc. was a big mover last session, as its shares rose over 12% on the day.
Douglas L. Mayers Thanks Teri. I’m happy to provide you an update on the progress of IDX21437. This morning, we are now topline data from our seven-day proof-of-concept study. As a reminder, we initiate ...
Idenix Pharma (IDIX) Updates on IDX21437 in HCV; Plans mid-2014 Initiation of Phase II with SamatasvirStreet Insider 04/07 07:52 ET
Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis CGlobeNewswire 04/07 07:00 ET
CAMBRIDGE, Mass. -- Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced continued progress ...